Type 2 Diabetes: A Complete Guide to Prevention, Diagnosis, and Daily Management
Type 2 diabetes is the most common metabolic disease worldwide: in Italy, there are 3.7 million diagnosed diabetics, and it is estimated that another 1.5 million are not yet aware they have it. This guide explains everything you need to know: from causes to diagnosis, from therapeutic goals to daily monitoring tools.
What is Type 2 Diabetes
Type 2 diabetes mellitus is a chronic metabolic disease characterized by persistent hyperglycemia — chronically elevated blood glucose levels. It develops through two mechanisms that often coexist:
- Insulin resistance: muscle, fat, and liver cells do not respond adequately to insulin, reducing glucose uptake
- Progressive deficit in insulin secretion: the pancreas cannot produce enough insulin to compensate for the resistance
The result is a chronic increase in blood glucose which, over time, damages blood vessels, nerves, kidneys, retina, and heart.
Epidemiological Data in Italy
- 3.7 million Italians have diagnosed diabetes (ISS 2025)
- 90–95% of cases are type 2 diabetes
- Approximately 1.5 million are undiagnosed diabetics
- Over 4 million have pre-diabetes
- The direct cost of diabetes to the NHS is €9.2 billion/year (Osservasalute 2024)
- Diabetes is responsible for 40% of non-traumatic lower limb amputations and 30% of cases of end-stage renal failure
Risk Factors
Non-modifiable
- Age > 45 years (risk doubles every decade after 40)
- Family history (parent or sibling with type 2 diabetes: 2–4 times higher risk)
- Previous gestational diabetes or child born > 4.5 kg
- Ethnicity (Asian, African, Latin American populations have a higher risk)
Modifiable (which you can act on)
- Overweight/obesity: the main modifiable risk factor; BMI > 25 triples the risk
- Visceral fat: independently of weight, abdominal fat distribution is an autonomous risk factor
- Sedentary lifestyle: increases risk by 30–50%
- High GI diet: high consumption of sugary drinks, refined carbohydrates
- Pre-diabetes: fasting glucose 100–125 mg/dL or OGTT 140–199 mg/dL
- Arterial hypertension: concomitant presence increases risk by 40%
- Dyslipidemia: high triglycerides and low HDL (metabolic syndrome)
- Sleep apnea: associated with insulin resistance
Diagnosis: Official Criteria
The diagnosis of diabetes mellitus requires one of the following criteria, confirmed in two separate blood tests (unless classic symptoms + random glucose ≥ 200 mg/dL):
| Test | Diabetes threshold | Pre-diabetes threshold |
|---|---|---|
| Fasting glucose (≥8h) | ≥ 126 mg/dL | 100–125 mg/dL |
| OGTT 2h (75 g glucose) | ≥ 200 mg/dL | 140–199 mg/dL |
| HbA1c | ≥ 6.5% | 5.7–6.4% |
| Random glucose | ≥ 200 mg/dL + symptoms | — |
Source: ADA Standards of Care 2025; Standard Italiani AMD-SID 2024.
Symptoms of Type 2 Diabetes
Unlike type 1, type 2 diabetes develops slowly and can be asymptomatic for years. When symptoms appear:
- Polyuria: frequent and abundant urination
- Polydipsia: intense and persistent thirst
- Chronic fatigue and loss of energy
- Blurred vision (excess glucose alters the shape of the lens)
- Slow healing of wounds
- Recurrent infections (urinary, skin, candidiasis)
- Tingling or numbness in the feet (early peripheral neuropathy)
- Unintentional weight loss (less common than in type 1)
Glycemic Targets for Type 2 Diabetes in Treatment
| Parameter | Standard target | Healthy elderly target | Frail elderly target |
|---|---|---|---|
| HbA1c | < 7.0% | < 7.5% | < 8.0–8.5% |
| Fasting glucose | 80–130 mg/dL | 90–150 mg/dL | 100–180 mg/dL |
| 2h postprandial glucose | < 180 mg/dL | < 200 mg/dL | < 220 mg/dL |
| Blood pressure | < 130/80 mmHg | < 140/90 mmHg | < 150/90 mmHg |
| LDL-cholesterol | < 70 mg/dL | < 70–100 mg/dL | Individualized |
Source: AMD-SID Italian Standards 2024; ESC Guidelines on Cardiovascular Disease Prevention 2023.
Pharmacological Therapy for Type 2 Diabetes
Therapy is personalized based on the patient's profile, cardiovascular risk, renal function, and individual preferences:
First line
- Metformin: first-choice drug, reduces HbA1c by 1–2%, provides cardiovascular protection, weight-neutral, inexpensive. To be taken with meals to reduce gastrointestinal effects.
Cardiovascularly protective drugs (preferred in patients at high CV risk)
- SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin): reduce HbA1c, weight (-2–4 kg), blood pressure, and have demonstrated cardio and nephroprotective effects
- GLP-1 agonists (semaglutide, dulaglutide, liraglutide): significantly reduce HbA1c and weight (-4–10 kg), reduce cardiovascular events, injectable (weekly or daily)
Second-line drugs
- DPP-4 inhibitors (sitagliptin, vildagliptin): weight-neutral, well-tolerated, moderate efficacy
- Sulfonylureas: effective but risk of hypoglycemia and weight gain
- Basal insulin: when targets are not achievable with oral medications
Lifestyle: The Most Powerful Intervention
Lifestyle changes reduce HbA1c by 1–2% — as much as a second-line drug — and simultaneously address all cardiovascular risk factors:
- Weight loss: every 1 kg lost improves fasting glucose by 2–4 mg/dL. A 10–15% weight loss (with bariatric surgery or GLP-1) leads to diabetes remission in 30–60% of cases
- Physical activity: 150 min/week of aerobic + 2 resistance sessions reduce HbA1c by 0.5–1%
- Low GI diet: reduces postprandial glycemic excursions
- Sodium reduction: controls blood pressure (frequently elevated in diabetics)
Home Monitoring with a Glucometer
Self-monitoring of blood glucose (SMBG) is one of the most effective tools for managing type 2 diabetes. It allows you to:
- Verify the effectiveness of pharmacological therapy
- Identify meals that cause glycemic spikes
- Early recognize hypoglycemic episodes
- Provide objective data to the diabetologist to adjust therapy
Clinical studies show that patients with type 2 diabetes who perform regular SMBG and share data with their diabetologist have an average HbA1c that is 0.5% lower and a reduced risk of complications (BMJ Open Diabetes Research & Care 2023).
The VitaeChek G1 Pro is designed to make this monitoring simple: automatic Bluetooth, app with trend graph, shareable PDF report, and voice announcement of results in Italian.
Complications of Type 2 Diabetes: How to Prevent Them
Optimal glycemic control significantly reduces the risk of all chronic complications:
- Diabetic nephropathy: risk reduced by 35–40% for every 1% reduction in HbA1c
- Diabetic retinopathy: risk reduced by 25–35%
- Peripheral neuropathy: risk reduced by 25%
- Myocardial infarction: risk reduced by 14–16%
- Stroke: risk reduced by 12%
- Amputations: risk reduced by 40–50% with glycemic control + foot care
Frequently Asked Questions
Can type 2 diabetes be cured?
In some cases, yes — it is called "remission." With significant weight loss (≥10–15%), 30–60% of type 2 diabetics achieve normal blood glucose without medication for at least 1 year. Remission is more likely at the beginning of the disease and with rapid and sustained weight loss.
Can I stop medications if my blood glucose is at target?
Only under medical supervision. If lifestyle changes lead to a stable HbA1c below 6.5% for 3–6 months, the doctor may consider reducing therapy. Never stop on your own.
Does type 2 diabetes lead to type 1?
No — they are two distinct diseases with completely different mechanisms. Type 1 is autoimmune (the immune system destroys pancreatic beta cells); type 2 is metabolic (insulin resistance + relative insulin deficiency). You cannot "become" type 1 from type 2.
